Abstract
For treatment with cyclophosphamide (CP) rapid repair of CP-induced DNA interstrand cross-links (ICLs) seems to be an important problem in the lack of activity. This implies the idea of combined treatment of CP with nucleoside analogs such as fludarabine or gemcitabine,which should be able to inhibit repair of damaged DNA. Using multiple drug effect analysis we investigated the interaction between the cyclophosphamide prodrug 4-HC and the nucleoside of fludarabine, F-ara-A. Simultaneous exposure to the drug combination 4-HC/F-ara-A for 4 h resulted in synergistic reduction of clonogenicity in the lymphoblastic cell line CCRF-CEM. This finding was in agreement with repair experiments of 4-HC induced ICLs.After 4 h exposure to 10 µM 4-HC alone and washing into drug-free media, more than 80% of the ICLs were repaired after 6 h. In contrast, the retention of ICLs was increased in cells incubated with 4-HC in combination with F-ara-A, such that most of ICLs remained after 6 h. These results suggest a possible role of nucleoside analogs to suppress the repair of damaged DNA. This maybe a mechanistic basis for the synergistic cytotoxicity of combined treatment with alkylating agents and nucleoside analogs.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Chen TL, Passos-Coetho JL, Noe DA, Kennedy MJ, Black KC, Colvin M, Grochow BL (1995) Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous marrow transplantation. Cancer Res., 18: 810–816
Schuler U, Ehninger G, Wagner T (1987) Repeated high-dose cyclophosphamide administration in bone marrow transplantation: exposure to activated metabolites. Cancer Chemother Pharmacol., 20: 248–252
Yule SM, Boddy AV, Cole M, Price L, Wyllie R, Tasso MJ, Pearson ADJ, Idle JR (1995) Cyclophosphamide metabolism in children. Cancer Res., 55: 803–809
Rowley SD, Jones RJ, Piantadosi S, Braine HG, Colvin OM, Davis J, Saral R, Sharkis S, Ingard J, Yeager AM, Santos GW (1989) Efficacy of ex vivo purging for autologous bone marrow transplantation in the treatment of acute nonlymphoblastic leukemia. Blood 74: 501–506
DeNeve W, Valeriote F, Edelstein M, Everett C, Bischoff M (1989) In Vivo DNA Cross-Linking by cyclophosphamide: Comparison of human chronic lymphatic leukemia cells with mouse L1210 leukemia and normal bone marrow cells. Cancer Res., 49: 3452–3456
Wang JY, Porok G, Vaughan WP (1993) Cytotoxicity, DNA cross-linking, and DNA single-strand breaks induced by cyclophosphamide in rat leukemia in vivo. Cancer Chemother Pharmacol., 31: 381–386
Dong Q, Borsky D, Colvin ME, Melius C, Ludemann S, Moravek JF, Colvin OM, Bigner DD, Modrich P, Friedman HS (1995) A structural basis for a phosphoramide mustard-induced DNA interstrand cross-link at 5’-d(GAC). Biochemistry., 92: 12170–12174
Povirk LF, Shuker DE (1994) DNA damage and mutagenesis induced by nitrogen mustards. Mutation Res., 318: 205–226
Andersson BS, Mroue M, Britten RA, Murray D (1994) The role of DNA damage in the resistance of human chronic myeloid leukemia cells to cyclophosphamide analogues. Cancer Res., 54: 5394–5400
Garcia ST, McQuillan A, Panasci L (1988) Correlation between the cytotoxicity of Melphalan and DNA crosslinks as detected by the ethidium bromide fluorescence assay in the F1 variant of B16 melanoma cells. Biochem Pharmacol., 37: 3189–3192
Kastan MB, Schlaffer E, Russo JE, Colvin OM, Civin CI, Hilton J (1990) Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells. Blood 10: 1947–1950
McGrown AT, Fox BW (1986) A proposed mechanism of resistance to cyclophosphamide and phosphoramide mustard in aYoshida cell line in vitro. Cancer Chemother Pharmacol., 17: 223–226
Calsou P, Salles B (1993) Role of DNA repair in the mechanisms of cell resistance to alkylating agents and cisplatin. Cancer Chemother Pharmacol., 32: 85–89
Larminat F, Zhen W, Bohr AV (1993) Gene-specific DNA repair of interstrand cross-links induced by chemotherapeutic agents can be preferential. Biol Chemistry., 208: 2649–2654
Hemminski K, Ludlum DB (1984) Covalent modification of DNA by antineoplastic agents. J Natl Cancer Inst., 73: 1021–1028
Dong Q, Bullock N, Ali-Osman F, Colvin M, Signer DD, Friedman HS (1996) Repair analysis of 4-hydroperoxycyclophosphamide-induced interstrand crosslinking in the c-myc gene in 4hydroperoxycyclophosphamide-sensitive and -resistant medulloblastoma cell lines. Cancer Chemother Pharmacol., 37: 242–246
Keating M, O’Brien S, Plunkett W, Robertson LE, Gandhi V, Estey E, Dimopoulos M, Cabanillas F, Kemena A, Kantarjian H (1994) Fludarabine posphate: A new active agent in hematologic malignancies. Sem Hematol., 31: 28–39
Keating M, McLaughlin P, Plunkett W, Robertson LE, O’Brien S, Gandhi V, Gregoire V, Yang L, Cabanillas F (1994) Fludarabine–present status and future developments in chronic lymphocytic leukemia and lymphoma. Annals Oncol., 5: 79–83
Plunkett W, Gandhi V, Huang P, Robertson LE, Yang LY, Gregoire V, Estey E, Keating M (1993) Fludarabine: pharmacokinetics, mechanisms of action and rationales for combination therapies. Sem Oncology., 10: 2–12
Huang P, Plunkett W (1995) Fludarabine-and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event. Cancer Chemother Pharmacol., 36: 181–188
Tseng WC, Derse D, Cheng YC, Brockman RW, Bennett LL (1982) In vitro activity of 9- ß-Darabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells. Mol Pharmacol., 21: 474–477
Catapano C, Perrino FW, Fernandes DJ (1993) Primer RNA chain termination induced by 9ß-D-arabinofuranosyl-2-fluoro adenine 5-triphosphate: a mechanism of DNA synthesis inhibition. J Biol Chem., 268: 7179–7185
Kamiya K, Huang P, Plunkett W (1996) Inhibition of the 3–5 exonuclease of human DNA polymerase £ by fludarabine-terminated DNA. Biolog Chemistry., 271: 19428–19435
Lozzio GB, Lozzio BB (1975) Human chronic myelogenious leukemia cell line with positive Philadelphia chromosome. Blood., 45: 321–326
Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationship: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul., 22: 27–55
Chou TC, Talalay P (1988) Computerized simulation of dose reduction index (DRI) in synergistic drug combinations. Pharmacologist., 30: A231
Brent TP (1984) Supression of cross-link foramation in chloroethylnitrosourea-treated DNA by an activity in extracts of human leukemic lymphoblasts. Cancer Res., 44: 1887–1892
Yang LY, Li L, Keating MJ, Plunkett W (1995) Arabinofuranosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatinDNA cross-link repair. Molecular Pharmacol., 47: 1072–1079
Chresta CM, Crook TR, Souhami RL (1990) Depletion of cellular glutathione by N,N’-bis (trans-4-hydroxycyclohexyl)-N’-nitrosourea as a determinant of sensitivity of K562 human leukemia cells to 4-Hydroperoxycyclophosphamide. Cancer Res., 50: 4067–4071
Crook TR, Souhami RL, McLean AEM (1986) Cytotoxicity, DNA cross-linking, and single strand breaks induced by activated cyclophosphamide and acrolein in human leukemia cells. Cancer Res., 46: 5029–5034
Little SA, Mirkes PE (1987) DNA cross-linking and single-strand breaks induced by teratogenic concentrations of 4-hydroperoxycyclophosphamide and phosphoramide mustard in post-implantation rat embryos. Cancer Res., 47: 5421–5426
Hengstler JH, Fuchs J, Oesch F (1992) DNA strand breaks and DNA cross-links in peripherial mononuclear blood cells of ovarian cancer patients during chemotherapy with cyclophosphamide/carboplatin. Cancer Res., 52: 5622–5626
Hilton J (1984) Deoxyribonucleic acid cross-linking by 4-hydroperoxycyclophosphamide in cyclophosphamide-sensitive and resistant L1210 Cells. Biochem Pharmacol., 12: 1867–1872
Keating M, O’Brien S, McLaughlin P, Kantarjian H, Cabanillas F (1996) Fludarabine combinations in the management of chronic lymphocytic leukemia and low grade lymphoma. Annals of Oncology., 34, 110
Reed E, Kohn EC, Sarosy G, Dabholkar M, Davis P, Jacob J, Martha M (1995) Paclitaxel, cisplatin, and cyclophosphamide in human ovarian cancer: Molecular rationale and early clinical results. Seminars in Oncology., 3: 90–96
Cleaver JE (1994) It was a very good year for DNA repair. Cell., 76: 1–4
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Koehl, U. et al. (1998). Effect of Combined Treatment with 4-Hydroperoxycyclophosphamide and Fludarabine on Cytotoxicity and Repair of Damaged DNA. In: Hiddemann, W., et al. Acute Leukemias VII. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, vol 39. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-71960-8_73
Download citation
DOI: https://doi.org/10.1007/978-3-642-71960-8_73
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-71962-2
Online ISBN: 978-3-642-71960-8
eBook Packages: Springer Book Archive